Articles

Two Dosing Schedules of Pembrolizumab for Patients with Advanced Melanoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Updated OS Data for the CA184-043 Trial: Immunotherapy with Ipilimumab Does Not Improve Survival in Patients with Metastatic Prostate Cancer

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Afatinib Improves Outcomes in Patients with Head and Neck Cancer

ESMO 2014 - Gastrointestinal and Head & Neck Cancer, ESMO

Conference Correspondent

Association of HPV and p16 Status with Cetuximab plus Radiotherapy in Locally Advanced Head and Neck Cancer

ESMO 2014 - Gastrointestinal and Head & Neck Cancer, ESMO

Conference Correspondent

Pembrolizumab in HPV-Positive Head and Neck Cancer

ESMO 2014 - Gastrointestinal and Head & Neck Cancer, ESMO

Conference Correspondent

Cetuximab, Fluorouracil, and Cisplatin, with/without Docetaxel, in Recurrent or Metastatic Head and Neck Cancer

ESMO 2014 - Gastrointestinal and Head & Neck Cancer, ESMO

Conference Correspondent

Anti–PD-L1 Monoclonal Antibody MPDL3280A in Metastatic Urothelial Bladder Cancer

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Long-Term Follow-Up Results of MPDL3280A in Metastatic Renal-Cell Carcinoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Dose-Ranging Phase 2 Results of Nivolumab Therapy in Metastatic Renal-Cell Carcinoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Pembrolizumab in the Treatment of Patients with Advanced Urothelial Tract Cancer

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Page 214 of 329